Moleculin Shares Owned by Institutions

MBRX
 Stock
  

USD 1.47  0.02  1.38%   

Moleculin Biotech CS fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh

Moleculin Shares Owned by Institutions Analysis

Moleculin Biotech's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
 2021 2022 (projected)
Accounts Payable1.36 M1.2 M
Receivables23 K24.82 K
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
More About Shares Owned by Institutions | All Equity Analysis

Current Moleculin Biotech Shares Owned by Institutions

    
  14.67 %  
Most of Moleculin Biotech's fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moleculin Biotech CS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Moleculin Shares Owned by Institutions Driver Correlations

Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Shares Owned by Institutions. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 14.67% of Moleculin Biotech CS are shares owned by institutions. This is 67.14% lower than that of the Healthcare sector and 69.12% lower than that of the Biotechnology industry. The shares owned by institutions for all United States stocks is 62.59% higher than that of the company.

Moleculin Shares Owned by Institutions Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moleculin Biotech's direct or indirect competition against its Shares Owned by Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics of similar companies.
Moleculin Biotech is currently under evaluation in shares owned by institutions category among related companies.

Moleculin Biotech Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moleculin Biotech from analyzing Moleculin Biotech's financial statements. These drivers represent accounts that assess Moleculin Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moleculin Biotech's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(1.23 M)(913.54 K)(825.31 K)(1.15 M)(934.94 K)(1.01 M)
Average Assets20.42 M22.37 M27.2 M28.26 M91.53 M98.75 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(9.79 M)(11.81 M)(13.23 M)(17.16 M)(15.73 M)(16.14 M)
Earnings before Tax(9.8 M)(11.88 M)(13.43 M)(17.36 M)(15.89 M)(16.31 M)
Average Equity17.8 M16.64 M17.83 M15.79 M83.37 M89.95 M
Enterprise Value30.58 M19.61 M26.74 M37.19 M(21.95 M)(22.53 M)
Free Cash Flow(7.35 M)(12.62 M)(17.25 M)(18.14 M)(18.97 M)(19.47 M)
Invested Capital(1.59 M)(2.58 M)58 K(51 K)(1.52 M)(1.56 M)
Invested Capital Average(1.37 M)(2.15 M)(4.8 M)(107.75 K)(1.3 M)(1.41 M)
Market Capitalization39.31 M28.21 M41.85 M49.79 M53.15 M51.11 M
Tangible Asset Value8.34 M8.44 M14.09 M17.88 M72.94 M78.7 M
Working Capital6.09 M4.1 M9.91 M14.28 M68.88 M74.31 M

Moleculin Fundamentals

About Moleculin Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech CS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech CS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Moleculin Biotech Investors Sentiment

The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.

Current Sentiment - MBRX

Moleculin Biotech Investor Sentiment

Most of Macroaxis users are now bullish on Moleculin Biotech CS. What is your trading attitude regarding investing in Moleculin Biotech CS? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moleculin Biotech Piotroski F Score and Moleculin Biotech Altman Z Score analysis. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
41.2 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.